Supplementary Table I. Traditional and biological disease-modifying anti-rheumatic drugs used by patients according to country.

Therapy received, n (%)	France (n=124)	Germany (n=122)	Italy (n=127)	Spain (n=120)	UK (n=138)	All patients (n=631)	Responders (n=419)	Non-responders (n=156)
Current biological status								
Not currently receiving	61 (51)	83 (69)	90 (75)	80 (69)	86 (58)	400 (64)	232 (57)	116 (78)
Currently receiving	63 (49)	39 (31)	37 (25)	40 (31)	52 (42)	231 (36)	187 (43)	40 (22)
Biological DMARD (if currently receiving)								
Adalimumab	23 (36)	25 (66)	18 (51)	29 (72)	31 (60)	126 (55)	104 (56)	18 (44)
Certolizumab	2 (3)	0	1 (6)	0	1 (<1)	4 (2)	0	4 (15)
Etanercept	18 (34)	3 (6)	5 (12)	8 (23)	15 (29)	49 (24)	42 (26)	7 (18)
Golimumab	7 (15)	3 (6)	2 (4)	2 (4)	5 (10)	19 (9)	16 (9)	3 (6)
Infliximab	13 (12)	8 (23)	11 (27)	1 (2)	0	33 (10)	25 (9)	8 (16)
Other treatment								
Azathioprine	0	1 (<1)	0	1 (1)	0	2 (<1)	1 (<1)	1 (<1)
Hydroxyquinone	0	1 (<1)	13 (12)	0	0	14 (3)	14 (4)	0
Leflunomide	0	3 (<1)	1 (<1)	3 (4)	0	7 (<1)	6 (1)	1 (<1)
Methotrexate	12 (9)	19 (14)	27 (18)	18 (15)	15 (9)	91 (13)	62 (13)	28 (17)
Sulfasalazine	7 (5)	9 (7)	20 (19)	15 (13)	11 (6)	62 (10)	44 (11)	17 (11)
NSAID (other than COX2 inhibitor)	61 (50)	79 (70)	34 (27)	47 (42)	77 (59)	298 (49)	195 (49)	81 (55)
COX2 inhibitor	16 (15)	9 (5)	25 (16)	39 (28)	25 (15)	114 (16)	72 (15)	38 (25)
Non-opioid analgesic	34 (22)	15 (12)	32 (27)	11 (10)	6 (4)	98 (15)	66 (15)	30 (18)
Opioid analgesic	4 (2)	3 (3)	2 (2)	1 (<1)	6 (4)	16 (3)	5 (1)	10 (6)
Oral steroid	2 (1)	19 (14)	2 (1)	3 (2)	1 (<1)	27 (3)	10 (2)	15 (7)
Locally injected steroid	3 (<1)	7 (5)	0	0	9 (5)	19 (2)	11 (2)	8 (4)
Gastroprotective agent	29 (23)	34 (31)	22 (16)	19 (14)	26 (21)	130 (20)	75 (18)	50 (32)
None	30 (24)	22 (20)	19 (12)	19 (17)	18 (14)	108 (17)	74 (16)	4 (3)

Data source: Adelphi 2014 nr-axSpA Disease Specific Programme.
COX-2: cyclo-oxygenase-2; DMARD: disease-modifying anti-rheumatic drug; NSAID: non-steroidal anti-inflammatory drug.
Percentages, means, and standard deviations are weighted to adjust for design bias in the Disease Specific Programme methodology; frequencies are not weighted. Responders met all of the following criteria: the physician reported being satisfied with the patient's current disease control; the patient was not currently experiencing an acute episode and there was either an improvement in severity since initiation of current therapy or the patient's disease remained mild or moderate between time points. Non-responders were defined as those who did not meet these criteria.

Supplementary Table II. Balance diagnostics for propensity score matching for DSP patients *vs*. HSfE control subjects.

Covariate	HSfE sample		DSP sample		Standardised mean difference	
	Before matching (n=6319)	After matching (n=187)	Before matching (n=220)	After matching (n=187)	Before matching (%)	After matching (%)
Age (years), mean	49.3	42.8	43.5	42.7	-48.9	-1.0
Male, %	45.5	73.8	76.4	73.8	72.4	0.0
BMI (kg/m²), mean	27.4	25.3	25.3	25.2	-70.2	-0.9
Caregiver required, %	4.3	1.6	10.5	1.6	20.2	0.0
Endocrine/metabolic condition, %	9.1	5.9	10.5	5.9	4.3	0.0
Heart/circulatory system condition, %	11.5	4.3	5.9	4.3	-23.5	0.0
Respiratory system condition, %	7.5	0.0	2.3	0.0	-34.9	0.0
Digestive system condition, %	4.8	1.1	5.5	1.1	2.9	0.0
Employed, %	54.3	69.5	66.8	69.5	26.4	0.0
Homemaker, %	7.5	7.0	6.4	7.0	-4.7	0.0
Student, %	5.7	3.7	4.1	3.7	-8.0	0.0
Unemployed, %	7.1	10.7	11.8	10.7	14.5	0.0
Retired, %	25.4	9.1	10.9	9.1	-46.2	0.0
Outcome						
EQ-5D, mean	0.864	0.884	0.764	0.776	N/A	N/A

Data sources: Adelphi 2011 and 2014 nr-axSpA Disease Specific Programmes; HSfE database (1).
BMI: body mass index; DSP, Disease Specific Programme; EQ-5D: EuroQol 5-Dimensions questionnaire; HSfE: Health Survey for England; N/A: not applicable.

Supplementary Table III. Balance diagnostics for propensity score matching for responders *vs.* non-responders in the Disease Specific Programme population (EQ-5D).

Covariate	Responders		Non-responders		Standardised mean difference	
	Before matching (n=144)	After matching (n=67)	Before matching (n=67)	After matching (n=67)	Before matching (%)	After matching (%)
Age (years), mean	42.7	44.2	44.7	44.7	18.2	4.5
Male, %	77.1	73.1	74.6	74.6	-5.6	3.4
BMI (kg/m^2), mean	25.0	25.6	25.7	25.7	20.2	3.8
Caregiver required, %	6.9	14.9	17.9	17.9	28.4	7.7
Endocrine/metabolic condition, %	8.3	16.4	14.9	14.9	18.4	-4.2
Heart and circulatory system condition, %	6.3	4.5	6.0	6.0	-1.2	6.3
Respiratory system condition, %	2.1	3.0	3.0	3.0	5.3	0.0
Digestive system condition, %	5.6	4.5	6.0	6.0	1.7	6.3
Employed, %	70.8	58.2	56.7	56.7	-28.3	-3.0
Homemaker, %	4.9	10.4	10.4	10.4	18.1	0.0
Student, %	4.2	4.5	4.5	4.5	1.5	0.0
Unemployed, %	10.4	14.9	16.4	16.4	16.1	4.0
Retired, %	9.7	11.9	11.9	11.9	6.8	0.0
Outcome						
EQ-5D, mean	0.822	0.834	0.638	0.638	N/A	N/A

Data sources: Adelphi 2011 and 2014 nr-axSpA Disease Specific Programmes.
BMI: body mass index; EQ-5D: EuroQol 5-Dimensions questionnaire; N/A: not applicable.
Responders met all of the following criteria: the physician reported being satisfied with the patient's current disease control; the patient was not currently experiencing an acute episode and there was either an improvement in severity since initiation of current therapy or the patient's disease remained mild or moderate between time points. Non-responders were defined as those who did not meet these criteria.

Supplementary Table IV. Balance diagnostics for propensity score matching for responders *vs.* non.responders in the Disease Specific Programme population (activity impairment).

Covariate	Responders		Non-responders		Standardised mean difference	
	Before matching (n=135)	After matching (n=62)	Before matching (n=62)	After matching (n=62)	Before matching (%)	After matching (%)
Age (years), mean	42.4	44.5	44.9	44.9	22.2	3.8
Male, %	78.5	69.4	71.0	71.0	-16.5	3.5
BMI (kg/m^2), mean	25.0	25.4	25.6	25.6	16.0	4.4
Caregiver required, %	7.4	16.1	17.7	17.7	26.8	4.2
Endocrine/metabolic condition, %	8.9	14.5	14.5	14.5	15.8	0.0
Heart and circulatory system condition, %	5.9	6.5	6.5	6.5	2.1	0.0
Respiratory system condition, %	2.2	3.2	3.2	3.2	5.6	0.0
Digestive system condition, %	5.9	4.8	4.8	4.8	-5.0	0.0
Employed, %	73.3	62.9	59.7	59.7	-27.6	-6.5
Homemaker, %	4.4	11.3	11.3	11.3	21.5	0.0
Student, %	3.7	3.2	3.2	3.2	-2.7	0.0
Unemployed, %	11.1	11.3	14.5	14.5	9.6	9.1
Retired, %	7.4	11.3	11.3	11.3	12.2	0.0
Outcome						
Activity impairment, mean	27.6	33.3	47.4	47.4	N/A	N/A

Data sources: Adelphi 2011 and 2014 nr-axSpA Disease Specific Programmes. BMI: body mass index; N/A: not applicable. Responders met all of the following criteria: the physician reported being satisfied with the patient's current disease control; the patient was not currently experiencing an acute episode and there was either an improvement in severity since initiation of current therapy or the patient's disease remained mild or moderate between time points. Non-responders were defined as those who did not meet these criteria.

Reference
1. HEALTH AND SOCIAL CARE INFORMATION CENTRE: Health Survey for England 2012. Available at http://www.hscic.gov.uk/catalogue/PUB13218.